Skip to main content
. 2024 Mar 4;26:60. doi: 10.1186/s13075-024-03296-8

Table 2.

Subgroup analysis for the risk of vaccination with SLE

Subgroups Included studies OR
(95% CI)
Heterogeneity
I 2 (%) P-value
Region
North America 7 1.87 (0.99, 3.52) 73.2 0.053
Europe 7 0.96 (0.84, 1.10) 0.0 0.551
Asia 3 0.79 (0.30, 2.07) 93.9 0.628
Observation time
≥ 180 days 8 1.09 (0.89, 1.33) 0.0 0.408
< 180 days 8 1.13 (0.68, 1.87) 87.3 0.634
Study type
Case-control study 7 1.84 (1.03, 3.31) 75.9 0.041
Cohort study 10 0.85 (0.65, 1.11) 68.3 0.243